AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04272242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally
Study NCT04272242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally
Study NCT04272242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally
Study NCT04272242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
Study NCT04272242 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
Study NCT06597929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-vigorous physical activity
Description: The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
Study NCT06597929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity
Description: The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
Study NCT06592612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT and second-line systemic therapy
Description: Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
Study NCT06592612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line systemic therapy
Description: Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
Study NCT06593340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 1
Description: The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
Study NCT06593340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 2
Description: The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
Study NCT06593340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 1
Description: The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.
Study NCT06593340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 2
Description: The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
Study NCT06592365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GTE
Description: oral administration of GTE tablets once daily for 12 weeks
Study NCT06592365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo tablets once daily for 12 weeks
Study NCT06589219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMR316
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
Study NCT06589219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMR316
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
Study NCT06589219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
Study NCT06589375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sniffin'Sticks
Description: The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.
Study NCT06602557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
Study NCT06602557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
Study NCT06588127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nudge
Description: Nudge interventions are developed based on the scoping review and qualitative research by the research team, which involves commitment (behavioral contracts), norms (case and experience sharing), significance and framing effects (posters, health behavior identification posts), reminders, and incentives (arteriosclerosis detection). The content encompasses diet, physical activity, medication management, self-monitoring, and control of smoking and alcohol. From the viewpoint of bounded rationality in behavioral economics, and drawing on prior research that has pinpointed decision-making biases in patients' self-management behaviors, nudging strategies have been developed to assist individuals in overcoming these biases or to utilize the patterns of these biases to steer them toward making choices that are in line with their health.
Study NCT06604260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: 68Ga FAPi PET-CT scan
Study NCT06594952 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and Physical Exam
Description: Diagnosis of Anxiety using the state-trait anxiety inventory scale (STAI). Depression using Edinburgh Postnatal Depression Scale (EPDS)~* Coping using the Brief Coping Scale~* Socioeconomic using the Socioeconomic Scale of Egypt~* Personality using the short-form Eysenck Personality Questionnaire-Revised (EPQ-R)~* Behaviour using Impact of Erect Scale (IES-22)
Study NCT06594315 — intervention group
Intervention type: DRUG
Intervention: Deuterated Glucose
Description: Given orally
Study NCT06594315 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure performed at University of California, San Francisco
Study NCT06594315 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Capillary blood from the fingertip
Study NCT06594315 — intervention group
Intervention type: PROCEDURE
Intervention: MR spectroscopy (MRS)
Description: Imaging procedure performed at University of California, San Francisco
Study NCT06587867 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: efgartigimod
Description: active drug efgartigimod to be administer
Study NCT06586684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Patients with carotid plaques undergoing treatment with inclisiran
Study NCT06595901 — intervention group
Intervention type: OTHER
Intervention: Actigraph
Description: Participants will wear an Actigraph hip-worn accelerometer on their non-dominant hip during all waking hours, and on the wrist while sleeping
Study NCT06595901 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: * Patient Health Questionnaire Anxiety and Depression Scale30 (PHQ-ADS), a validated composite of anxiety and depressive symptoms.~* Self-reported cognition will be assessed by the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog).
Study NCT06595901 — intervention group
Intervention type: OTHER
Intervention: BrainBaseline application
Description: Objective measures of cognitive function will include those from the BrainBaseline application, a validated research tool developed by Digital Artefacts to remotely measure domains of cognition
Study NCT06595901 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured individual interviews will be conducted with up to 15 healthcare stakeholders and 15-30 patients with breast cancer at any time during the study period, as determined by participant preference.
Study NCT06600516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTi: Stimulus Control Core
Description: Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
Study NCT06600516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTi: Sleep Restriction Core
Description: Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
Study NCT06600516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTi: Sleep Compression Core
Description: Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
Study NCT06587542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of protein purified derivative
Description: Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion
Study NCT06600555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metabolic surgery with SLEEVE technique
Description: metabolic surgery with SLEEVE technique
Study NCT06600555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metabolic surgery with BY-PASS technique
Description: metabolic surgery with BY-PASS technique
Study NCT06586905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Multiplo Complete Syphilis (TP/nTP) Antibody Test
Study NCT06593535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Placebo trial)
Description: The Placebo capsule supplement was taken for 4 days (7 capsules per day)
Study NCT06593535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Placebo trial)
Description: The Placebo capsule supplement was taken for 4 days (7 capsules per day)
Study NCT06593535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astaxanthin (AST trial)
Description: The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
Study NCT06593535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Astaxanthin (AST trial)
Description: The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
Study NCT06602700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: high-intensity interval training
Study NCT06602700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT
Description: moderate-intensity continuous training
Study NCT06587698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 100 mg QD for 3 month
Study NCT06587698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BeiDouGen
Description: 60 mg BID for 3 month
Study NCT06587698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin+BeiDouGen
Description: 100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
Study NCT06547619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study NCT06547619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study NCT06595225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education sessions
Description: Participants received nutrition education each month, covering topics ranging from general nutrition knowledge, nutrition knowledge related to their diagnosis of living with HIV infection whether during the acute or chronic phase. In addition, specific information was shared about other comorbidities the participant could be living with, finally information was shared on ways to improve mental health and enhance physical activity levels.
Study NCT05878418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracolumbosacral Spinal Orthosis (TLSO)
Description: In the TE, PR, PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
Study NCT05878418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)
Description: The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
Study NCT05878418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)
Description: The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
Study NCT06586697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
Study NCT06705647 — intervention group
Intervention type: OTHER
Intervention: Chronic Obstructive Pulmonary Disease (COPD)
Description: The base line acoustic and mel frequency ceprtum coefficients will be analysed statistically between COPD voices and healthy control groups to highlight the correlation between COPD and its effects on voice production.
Study NCT06704412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: floss band
Description: The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot
Study NCT06704412 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
Study NCT06704828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4602
Description: SHR-4602
Study NCT06704568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group: Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
Study NCT06704399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy-Based Psychoeducation
Description: Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
Study NCT06704399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: No intervention will be applied to the control group.
Study NCT06705868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-Time-restricted eating (TRE)
Description: Ad libitum time-restricted scheme with a further time-restriction on fruit and vegetable consumption in participants with MASLD
Study NCT06705868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Management
Description: The SoC intervention refers to an adaptation of a healthier lifestyle in elements that have to do with weight management, adopting healthier dietary habits, alcohol intake reduction, increase physical activity levels.
Study NCT06351124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's
Description: Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.
Study NCT06279351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide+cetuximab+FOLFOX/FOLFIRI
Description: Thalidomide+cetuximab+FOLFOX/FOLFIRI